VIVUS – Qsymia’s Launch and Ex-US Partnership = Growth Drivers

July 2012 | 3 pages | ID: VAB52DEA814EN
MP Advisors

Abstracts

Approval of Qsymia (Qnexa – combination of phentermine and topiramate) by US FDA and launch by 4Q12 ahead of rival drug, Arena/Eisai's Belviq (loracaserin, 5-HT2C receptor agonist) should give Vivus (VVUS) the first mover advantage, as Qsymia already has a DEA controlled-substance classification while Belviq should become available by... Though Qsymia’s label is similar to Belviq, the discontinuation rules for Qsymia favor VVUS – discontinuation recommended at 14-wk and 28-wk if... Qsymia offers the best efficacy amongst the approved and drugs in pipeline for treating obesity, and we expect Qsymia to achieve worldwide peak sales... For more detail, please read our report released on July 19, 2012 on VVUS, titled “Qsymia’s Launch and Ex-US Partnership = Growth Drivers

Contents

COMPANIES MENTIONED

Vivus